Search
Scam alert
Beware of unauthorized or fraudulent hotel and registration booking agencies. INTERPLAN AG is the official housing bureau for the EHA2025 Congress.
Read moreAccommodation
Welcome to the Hotel Accommodation page for the EHA2025 Congress. Hotel Information and Official Housing Bureau
INTERPLAN AG is the official housing bureau for the EHA2025 Congress.
Dates and deadlines
You may find in this page all the dates and deadlines related to the EHA2025 Congress. All deadlines, except if mentioned differently, end at 23:59 CET/CEST.
The timelines will be updated regularly.
Program
Saturday, June 15, 2024 - Presidential Session I
Conducting multinational RCTs in pregnancy to improve maternal health in thrombosis: it CAN be done
Prof. Saskia Middeldorp, The Netherlands
Targeting the epigenome in lymphoma
Prof.
General Information
June 5, 2025
EHA2025 Congress platform opens
June 12-15, 2025
EHA2025 Milan, Italy - In-person and live stream
Location
Allianz MiCo, Milano Convention Centre
August 15, 2025
EHA2025 Congress platform closes
Scientific Program Committee (SPC) Chair
Prof.
Travel Grants
Travel grant application is now closed. Travel grants are intended to support young investigators to participate in the 7th European CAR T-cell Meeting; therefore, applicants should be 40 years of age or younger.
Read more7th European CAR T-cell Meeting
The European Hematology Association (EHA) and the EBMT are excited to announce the 7th edition of the jointly organized European CAR T-cell Meeting.
Read moreBoard
The EHA Board is the governing body of the association and deals with issues of policy. The Board sets the goals and objectives of the association in conformity with the EHA's statutes.
Read moreLighting the Flame Journal Club
A learning and connecting hematology experience led by alumni of the Lighting the Flame program. The Lighting the Flame Journal Club is an online group that's open to all members of the Lighting the Flame community.
Read moreSelected EMA news
December 2024New information on approved medicines
Sarclisa (isatuximab) - new indication
Treatment of multiple myeloma (a type of blood cancer)
Withdrawal of applications for extension of indication
Inaqovi (cedazuridine / decitabine)
Treatment of different types of blood cancer
Direct Healthcare Professional Communication (DHPC)
Pegasys (peginterferon alfa-2a)
Treatment of…
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- »